Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	6.31	8.33	15.45	2.5	-	-
Revenue Growth (YoY)	-36.36%	-46.07%	517.55%	-	-	-
Gross Profit	6.31	8.33	15.45	2.5	-	-
Selling, General & Admin	31.66	28.95	30.05	37.36	41.32	11.11
Research & Development	76.78	66	56.78	91.17	131.94	31.89
Operating Expenses	108.44	94.95	86.83	128.53	173.27	43
Operating Income	-102.13	-86.62	-71.37	-126.03	-173.27	-43
Interest Expense	-0.07	-0.1	-5	-3.8	-1.43	-0.03
Interest & Investment Income	8.05	6.94	3.57	0.25	0.17	0.05
Other Non Operating Income (Expenses)	-1.2	-0.09	-34.77	-0.02	-	-17.03
EBT Excluding Unusual Items	-95.35	-79.88	-107.57	-129.59	-174.52	-60.01
Asset Writedown	-	-4.84	-1.07	-36.42	-	-
Other Unusual Items	-4.58	-4.58	-2.94	-	-	-
Pretax Income	-99.93	-89.3	-111.57	-166.01	-174.52	-60.01
Net Income	-99.93	-89.3	-111.57	-166.01	-174.52	-60.01
Net Income to Common	-99.93	-89.3	-111.57	-166.01	-174.52	-60.01
Shares Outstanding (Basic)	297	250	116	44	38	18
Shares Outstanding (Diluted)	297	250	116	44	38	18
Shares Change (YoY)	26.22%	115.41%	164.20%	16.74%	113.13%	83.53%
EPS (Basic)	-0.34	-0.36	-0.96	-3.78	-4.64	-3.40
EPS (Diluted)	-0.34	-0.36	-0.96	-3.78	-4.64	-3.40
Free Cash Flow	-85.16	-81.6	-76.89	-109.01	-132.35	-30.81
Free Cash Flow Per Share	-0.29	-0.33	-0.66	-2.48	-3.52	-1.74
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-1618.54%	-1039.49%	-461.94%	-5037.05%	-	-
Profit Margin	-1583.66%	-1071.62%	-722.06%	-6635.25%	-	-
Free Cash Flow Margin	-1349.63%	-979.23%	-497.62%	-4356.88%	-	-
EBITDA	-100.98	-85.38	-70	-124.86	-172.78	-42.99
D&A For EBITDA	1.15	1.25	1.37	1.17	0.49	0.01
EBIT	-102.13	-86.62	-71.37	-126.03	-173.27	-43

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q